How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-myelocytic-leukemia-accelerated-phase.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic Myelocytic Leukemia Accelerated Phase — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic Myelocytic Leukemia Accelerated Phase (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic Myelocytic Leukemia Accelerated Phase, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Bosulif	bosutinib	Pfizer	Kinase Inhibitor	Tyrosine-protein kinase ABL1	2012-01-01
Bosulif	Bosutinib Monohydrate	Pfizer	Kinase Inhibitor	Tyrosine-protein kinase ABL1	2012-01-01
Tasigna	NILOTINIB	Cipla	Kinase Inhibitor [EPC]	Bcr/Abl fusion protein	2007-01-01
Sprycel	dasatinib	Handa Therap	dasatinib	Ephrin type-B receptor 6	2006-01-01
Gleevec	imatinib	Novartis	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-2	2001-01-01
Gleevec	Gleevec	M.D. Anderson Cancer Center		Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X
Tasigna	Tasigna	XSpray Microparticles		Ferrochelatase, mitochondrial, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase MRCK beta

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Chronic Myelocytic Leukemia Accelerated Phase
Cipla · 1 drug in Chronic Myelocytic Leukemia Accelerated Phase
Handa Therap · 1 drug in Chronic Myelocytic Leukemia Accelerated Phase
M.D. Anderson Cancer Center · 1 drug in Chronic Myelocytic Leukemia Accelerated Phase
Novartis · 1 drug in Chronic Myelocytic Leukemia Accelerated Phase
XSpray Microparticles · 1 drug in Chronic Myelocytic Leukemia Accelerated Phase

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic Myelocytic Leukemia Accelerated Phase:

Cite this brief

Drug Landscape (2026). Chronic Myelocytic Leukemia Accelerated Phase — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-myelocytic-leukemia-accelerated-phase. Accessed 2026-06-10.

Chronic Myelocytic Leukemia Accelerated Phase full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing